![]() Thrombotic events rates were low and consistent with the entire study cohort. Idarucizumab, a humanized monoclonal antibody fragment, reverses dabigatran anticoagulation. No trauma patient received more than one dose of idarucizumab, all patients had 100% reversal, and no drug-related adverse events were reported. Other injuries included fractured ribs, broken nose, and severed fingers. The most commonly documented mechanism of injury was fall from standing height, resulting in open or closed head injury or pelvic or hip fractures 6 patients sustained high-impact polytrauma. ![]() Results: Of the 503 patients enrolled in RE-VERSE AD, there were 114 trauma victims, 80 enrolled in Group A and 34 in Group B (Table). All patients were given 5 grams of idarucizumab intravenously and the primary endpoint was maximum reversal of dabigatran anticoagulation in the first 4 hours, as measured by ecarin clot time or diluted thrombin time. Methods: Trauma patients on dabigatran could be enrolled in either group in RE-VERSE-AD, whether for serious bleeding or for reversal prior to urgent surgery. When a patient needs an immediate reversal. ![]() It is a monoclonal antibody fragment created and produced by the German pharmaceutical company Boehringer Ingelheim. Idarucizumab is a medication used as a countermeasure to the oral Factor IIa (FIIa) inhibitor anticoagulant. This analysis focuses on the outcomes in the cohort of trauma patients. All tutors are evaluated by Course Hero as an expert in their subject area. Enrollment was based solely on the clinical decision to reverse anticoagulation. Background: Idarucizumab is licensed for dabigatran reversal based on the results of the RE-VERSE AD study, which showed rapid and complete reversal of dabigatran anticoagulation in patients presenting with severe bleeding (Group A), or in those requiring urgent surgery (Group B).
0 Comments
Leave a Reply. |